Inoue Kosuke, Yamazaki Yuto, Tsurutani Yuya, Suematsu Sachiko, Sugisawa Chiho, Saito Jun, Omura Masao, Sasano Hironobu, Nishikawa Tetsuo
Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan.
Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Horm Metab Res. 2017 Nov;49(11):847-853. doi: 10.1055/s-0043-119878. Epub 2017 Oct 25.
Aldosterone-producing adenoma (APA) is sometimes accompanied with subclinical hypercortisolism. We investigated the ability of cortisol production in APA, both clinically and pathologically. A retrospective cohort study was conducted at Yokohama Rosai Hospital from 2009 to 2016. Thirty patients with APA and serum cortisol levels during the 1 mg dexamethasone suppression test (F-DST)<3.0 μg/dl were included. We evaluated the 1) difference between pre-adrenalectomy F-DST (pre-F-DST) and post-adrenalectomy F-DST (ΔF-DST), 2) correlation between ∆F-DST and pre-F-DST, tumour size determined by CT, and type of adrenalectomy (total or partial), and 3) relationship between the ratio of F-DST divided by tumour size (ΔF-DST/pre-F-DST/mm) and immunoreactivity of CYP17A1, CYP11B1, and CYP11B2. The median [interquartile range] age was 48 [38-58] years. We found a significant decrease in F-DST after adrenalectomy [before: 1.4 (1.1-1.8); after: 0.9 (0.6-1.2); p<0.001]. Additionally, a significant correlation was found for ΔF-DST and both pre-F-DST (Spearman, ρ=-0.68, p<0.001) and tumour size (ρ=-0.51, p 0.005). No significant difference was found in ΔF-DST between total and partial adrenalectomy. CYP17A1 and CYP11B1 were positive in 21 (100%) and 17 (81%) adenomas, respectively. CYP17A1 immunoreactivity in the tumour was significantly related with ΔF-DST/pre-F-DST/mm (p 0.049). F-DST significantly decreased after adrenalectomy, and most of the adenomas were immunohistochemically positive for CYP17A1 and CYP11B1 as well as CYP11B2. We should consider the possibility of autonomous cortisol production as well as hyperaldosteronism in the evaluation and treatment of APA patients.
醛固酮瘤(APA)有时伴有亚临床皮质醇增多症。我们从临床和病理方面研究了APA中皮质醇的产生能力。2009年至2016年在横滨罗赛医院进行了一项回顾性队列研究。纳入了30例APA患者,且其在1毫克地塞米松抑制试验(F-DST)期间血清皮质醇水平<3.0μg/dl。我们评估了:1)肾上腺切除术前F-DST(术前F-DST)与肾上腺切除术后F-DST(ΔF-DST)之间的差异;2)ΔF-DST与术前F-DST、CT测定的肿瘤大小以及肾上腺切除术类型(全切或部分切除)之间的相关性;3)F-DST除以肿瘤大小的比值(ΔF-DST/术前F-DST/mm)与CYP17A1、CYP11B1和CYP11B2免疫反应性之间的关系。年龄中位数[四分位间距]为48[38 - 58]岁。我们发现肾上腺切除术后F-DST显著降低[术前:1.4(1.1 - 1.8);术后:0.9(0.6 - 1.2);p<0.001]。此外,发现ΔF-DST与术前F-DST(Spearman相关系数,ρ = -0.68,p<0.001)和肿瘤大小(ρ = -0.51,p = 0.005)均存在显著相关性。肾上腺全切和部分切除之间的ΔF-DST未发现显著差异。21例(100%)腺瘤中CYP17A1呈阳性,17例(81%)腺瘤中CYP11B1呈阳性。肿瘤中CYP17A1免疫反应性与ΔF-DST/术前F-DST/mm显著相关(p = 0.049)。肾上腺切除术后F-DST显著降低,并且大多数腺瘤在免疫组化中CYP17A1、CYP11B1以及CYP11B2均呈阳性。在APA患者的评估和治疗中,我们应考虑自主产生皮质醇以及醛固酮增多症的可能性。